Serelaxin treatment does not reduce incidence of death in patients with AHF

Nature Reviews Cardiology, Published online: 02 September 2019; doi:10.1038/s41569-019-0264-4

In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure.


No Comments

Write a Reply or Comment